YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Eurozone inflation recently topped forecasts and hit a three year high, which keeps pressure on central banks and pushes investors toward areas where returns depend more on scientific progress than economic cycles. That spotlight helps Bri…
LONDON, Sept. 10, 2026 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma, Group) announces that regulatory submissions for its epinephrine nasal spray, being developed for the emergency treatment of allergic reactions (anaphylaxis), have be…
Price targets for Hikma Pharmaceuticals are currently clustered in the £1,870 to £2,100 range, which sits above the latest fair value estimate of £19.70. Analysts linking these higher targets to Hikma Pharmaceuticals point to confidence in…
Citi sees Hikma discount as unwarranted after upgrade to forecasts Proactive uses images sourced from Shutterstock Citi has raised its estimates for Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) following stronger-than-expected half-year…
Hikma jumps 10% as brokers point to profit beat and undemanding rating Proactive uses images sourced from Shutterstock Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) shares rose 10% to 1,721p after first-half results came in ahead of expec…
Citi starts Hikma at 'buy' with strategy reset offering compelling entry point Proactive uses images sourced from Shutterstock Citi has initiated coverage of Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) with a 'buy' rating and a £17 pric…
Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Generic Drug Market size & share revenue was valued at approximately USD 491.35 Billi…
LONDON, June 4, 2026 /PRNewswire/ -- Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc., (Hikma) offered the following comments on today's unanimous decision by the Supreme Court of the United…
[Supreme Court of the United States. Washington DC, USA.] Mindaugas Dulinskas The Supreme Court unanimously sided with generic drugmaker Hikma (HKMPF [https://seekingalpha.com/symbol/HKMPF]) and against Amarin Corp. (AMRN [https://seekinga…
Cleveland and Columbus, Ohio, June 01, 2026 (GLOBE NEWSWIRE) -- COLUMBUS and CLEVELAND, Ohio – Ohio Governor Mike DeWine, along with Hikma Pharmaceuticals, JobsOhio, the City of Bedford, and other state and local partners, today announced…
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Hikma Pharmaceuticals has seen its model fair value edge from £18.8…
Pfizer Inc. (NYSE:PFE) is one of the most active US stocks to buy right now. On April 28, Pfizer entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals, and Cipla Ltd, resolving patent infri…
NEW YORK, April 28, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regarding lawsuits filed…
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. The fair value price target for Hikma Pharmaceuticals has been adjusted slightly from £19.02 to £…
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Hikma Pharmaceuticals’ fair value estimate has been trimmed slightl…
Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The "Renal Cell Carcinoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides a comprehensive analysis, depicting global market size, regional shares, comp…
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. The modelled fair value for Hikma Pharmaceuticals has been cut from £20.47 to £19.06 per share, with published price ta…
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Hikma Pharmaceuticals is back in focus after its fair value estimate was trimmed from £21.82 to £20.47. This shift has…
This article first appeared on GuruFocus. EBITDA Margins: 25%, outperforming competitors aiming for 22%. EBIT for Generic Business: GBP 100 million with margins close to 20%. R&D Budget: Targeting 5% to 6% of spending. Release Date: Februa…
* ClearBridge International Value Strategy outperformed its benchmark in Q4 2025, as the MSCI EAFE Index rose 4.9% during the quarter, compared with a 2.7% increase in the S&P 500. * During Q4 2025, the strategy initiated new positions in…
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. The latest update on Hikma Pharmaceuticals focuses on the price tar…
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Hikma Pharmaceuticals is back in focus after analysts revised their price target, reflecting a fres…
Appointment Enhances Leadership Team with Deep Sterile Injectables Expertise and Ability to Drive the Company's Global R&D Strategy and Execution ST. LOUIS, Jan. 12, 2026 /PRNewswire/ -- Par Health, Inc. ("Par Health" or the "Company") tod…
Hikma Pharmaceuticals’ fair value estimate has been nudged down from £22.66 to £22.00 per share, a small adjustment that better reflects the current mix of bullish and bearish analyst targets. The latest research includes optimistic calls…
The main aim of stock picking is to find the market-beating stocks. But in any portfolio, there will be mixed results between individual stocks. At this point some shareholders may be questioning their investment in Hikma Pharmaceuticals P…
Hikma Pharmaceuticals’ latest valuation update points to a slightly lower fair value estimate of about $22.66 per share, even as analysts broadly maintain a constructive view on its long term growth story. The modest trim in the central pr…
Ready-to-use sepsis therapy marks new advancement in time-critical treatment LONDON, Dec. 8, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces the launch of the first-of-its-k…
Hikma Pharmaceuticals' consensus analyst price target has seen a slight dip, moving from £23.55 to £23.36 per share. This adjustment comes as recent research indicates tempered optimism about the company’s growth outlook, coupled with a mo…
Hikma Pharmaceuticals has recently seen its fair value estimate reduced from £25.40 to £23.55, as analysts update their assessments in light of evolving business conditions. This modest downward revision reflects some caution regarding nea…
Find insight on AstraZeneca, Smith & Nephew, Novo Nordisk and more in the latest Market Talks covering Health Care. Continue Reading View Comments
The Ritedose Corporation Ritedose receives FDA approval for TobramycinTobramycin expands nation's largest nebulized drug portfolio. - Generic Tobramycin Inhalation Solution marks the first cystic fibrosis (CF) product in the Company’s port…
The consensus analyst price target for Hikma Pharmaceuticals has increased slightly, rising from £25.02 to £25.40 in the most recent updates. This adjustment reflects an ongoing reassessment by analysts, who weigh optimism for Hikma’s core…
The FTSE 100 hit another record high on Wednesday, despite concerns over the US shutdown, as pharmaceutical stocks powered higher, with AstraZeneca up 11% alone. The FTSE 100 index closed up 96.00 points, 1.0%, at 9,446.43, beating its pre…
Roche Holding and AstraZeneca were among those companies posting increases as European pharma stocks tracked gains in the U.S. on Tuesday. Continue Reading View Comments
Key Insights Institutions' substantial holdings in Hikma Pharmaceuticals implies that they have significant influence over the company's share price 51% of the business is held by the top 10 shareholders Insiders have bought recently This…
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage to find investors. Sometimes these stor…